Advertisement

Clinical Reviews in Allergy & Immunology

, Volume 38, Issue 2–3, pp 307–318 | Cite as

Intravenous Immunoglobulin in Lupus Panniculitis

  • João Espírito SantoEmail author
  • M. F. Gomes
  • M. J. Gomes
  • L. Peixoto
  • S. C. Pereira
  • A. Acabado
  • J. Freitas
  • G. Vinhas de Sousa
Article

Abstract

Systemic lupus erythematosus (SLE) is a disease of unknown cause that may involve one or many organ or systems. Skin involvement is a major feature in this disease, and a wide variety of skin conditions may be present. Lupus erythematosus panniculitis (LEP) constitutes a rare form of cutaneous lupus characterized by recurrent nodular or plaque lesions that can vary from a benign and mild course to a more disfiguring disease. Initial therapy includes corticosteroids, antimalarials, and azathioprine and, in refractory cases, two antimalarials in association, mycophenolate mofetil, or other immunomodulators. Intravenous immuglobulin (IVIG) is used in many autoimmune disorders, like in SLE, although clinical trials have not yet taken place. In this report, we review skin manifestations of SLE and their treatment, IVIG, and finally a case of LEP successfully treated with IVIG when other therapy modalities failed.

Keywords

SLE Skin manifestations of SLE LEP IVIG 

References

  1. 1.
    Tan EM et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277CrossRefPubMedGoogle Scholar
  2. 2.
    Ullrich SE (2000) Sun exposure and the lupus patient. Lupus Awareness 22:6–7Google Scholar
  3. 3.
    Vila LM, Mayor AM, Valentin AH et al (1999) Association of sunlight exposure and photoprotection measures with clinical outcome in systemic lupus erythematosus. Puerto Rico Health Sci J 18:89–94Google Scholar
  4. 4.
    Doria A et al (1996) Photosensitivity in systemic lupus erythematosus: laboratory testing of ARA/ACR definition. Lupus 5:263–268CrossRefPubMedGoogle Scholar
  5. 5.
    Hochberg MC et al (1985) Systemic lupus erythematosus: a review of clinico-laboratory features and immunogenetic markers in 150 patients with emphasis on demographic subsets. Medicine 64:285–295CrossRefPubMedGoogle Scholar
  6. 6.
    Mikle MF, Barton EN, Morgan OS, Deceulaer K (1996) Photosensitivity and antinuclear antibodies in black patients with systemic lupus erythematosus. J Assoc Acad Minor Phys 7:53–55Google Scholar
  7. 7.
    Sontheimer RD et al (1982) Serologic and HLA associations in subacute cutaneous lupus erythematosus, a clinical subset of lupus erythematosus. Ann Intern Med 97:664–671PubMedGoogle Scholar
  8. 8.
    Callen JP, Klein J (1988) Subacute cutaneous lupus erythematosus. Clinical, serologic, immunogenetic, and therapeutic considerations in seventy two patients. Arthritis Rheum 31:1007–1013CrossRefPubMedGoogle Scholar
  9. 9.
    Herrero C et al (1988) Subacute cutaneous lupus erythematosus: clinicopathologic findings in thirteen cases. J Am Acad Dermatol 19:1057–1062CrossRefPubMedGoogle Scholar
  10. 10.
    Sontheimer RD, Provost TT (1996) Lupus erythematosus. In: Sontheimer RD, Provost TT (eds) Cutaneous manifestations of rheumatic diseases. Williams and Wilkins, Baltimore, pp 1–71Google Scholar
  11. 11.
    Tuffanelli DL (1971) Lupus erythematosus panniculitis (profundus). Arch Dermatol 103:231–242CrossRefPubMedGoogle Scholar
  12. 12.
    Provost TT (1979) Lupus band test. In: Beutner EH, Chorzelski TP, Bean SF (eds) Immunopathology of the skin, vol 22. Wiley, New York, pp 399–410Google Scholar
  13. 13.
    Burnham TK, Fine G (1971) The immunofluorescent “band” test for lupus erythematosus. III. Employing clinically normal skin. Arch Derm 103:24–32CrossRefPubMedGoogle Scholar
  14. 14.
    Levy Y, Sherer Y, Ahmed A, Langevitz P, George J, Fabbrizzi F, Terryberry J, Meissner M, Lorber M, Peter JB, Shoenfeld Y (1999) A study of 20 SLE patients with intravenous immunoglobulin clinical and serologic response. Lupus 8:705CrossRefPubMedGoogle Scholar
  15. 15.
    Strober BE (2001) Lupus panniculitis (lupus profundus). Dermatology Online Journal 7(2):20 New York University, Department of DermatologyPubMedGoogle Scholar
  16. 16.
    Wimmershoff MB, Hohenleutner U, Landthaler M (2003) Discoid lupus erythematosus and lupus profundus in childhood: a report of two cases. Pediatr Dermatol 20:140–145PubMedGoogle Scholar
  17. 17.
    Bacanli A, Uzun S, Ciftcioglu MA, Alpsoy E (2005) A case of lupus erythematosus profundus with unusual manifestations. Lupus 14:403CrossRefPubMedGoogle Scholar
  18. 18.
    Chen MT, Chen KS, Chen MJ et al (1999) Lupus profundus (panniculitis) in a chronic haemodialysis patient. Nephrol Dial Transplant 14:966–968CrossRefPubMedGoogle Scholar
  19. 19.
    Martens PB, Moder KG, Ahmed I (1999) Lupus panniculitis: clinical perspectives from a case series. J Rheumatol 26:68–72PubMedGoogle Scholar
  20. 20.
    Kundig TM, Trueb RM, Krasovec M (1997) Lupus profundus=panniculitis. Dermatology 195:99–101CrossRefPubMedGoogle Scholar
  21. 21.
    Watanabe T, Tsuchida T (1996) Lupus erythematosus profundus: a cutaneous marker for a distinct clinical subset? Br J Dermatol 134:123–125CrossRefPubMedGoogle Scholar
  22. 22.
    Ng PP, Tan SH, Tan T (2002) Lupus erythematosus panniculitis: a clinicopathologic study. Int J Dermatol 41:488–490CrossRefPubMedGoogle Scholar
  23. 23.
    Grossberg E, Scherschun L, Fiven DP (2001) Lupus profundus: not a benign disease. Lupus 10:514CrossRefPubMedGoogle Scholar
  24. 24.
    Cernea SS, Kihara SM, Sotto MN et al (1993) Lupus mastitis. J Am Acad Dermatol 29:343–346CrossRefPubMedGoogle Scholar
  25. 25.
    Holland NW, McKnight K, Challa VR et al (1995) Lupus panniculitis (profundus) involving the breast: report of 2 cases and review of the literature. J Rheumatol 22:344–346PubMedGoogle Scholar
  26. 26.
    White WL, Sherertz EF, Berg D et al (1993) Periparotid lupus erythematosus panniculitis: clinicopathologic correlation of two cases presenting as primary parotid disease. Arch Pathol Lab Med 117:535–539PubMedGoogle Scholar
  27. 27.
    Ogura N, Fujisaku A, Jodo S et al (1997) Lupus erythematosus profundus around the salivary glands: a case resembling submandibular gland disease. Lupus 6:477–479CrossRefPubMedGoogle Scholar
  28. 28.
    Peters MS, Su WP (1989) Lupus erythematosus panniculitis. Med Clin North Am 73:1113–1126PubMedGoogle Scholar
  29. 29.
    Laman SD, Provost TT (1994) Cutaneous manifestations of lupus erythematosus. Rheum Dis Clin North Am 13:641–644Google Scholar
  30. 30.
    Tada J, Arata J, Katayama H (1991) Linear lupus erythematosus profundus in a child. J Am Acad Dermatol 24:871–874CrossRefPubMedGoogle Scholar
  31. 31.
    Heid E (1998) A 17-year old Italian boy with a linear lupus erythematosus profundus. Eur J Dermatol 8:69PubMedGoogle Scholar
  32. 32.
    Stork J, Vosmik F (1994) Lupus erythematosus panniculitis with morphea-like lesions. Clin Exp Dermatol 19:79–82CrossRefPubMedGoogle Scholar
  33. 33.
    Hytiroglou P, Phelps RG, Wattenberg DJ, Strauchen JA (1992) Cytophagic histiocytic panniculitis; molecular evidence for a clonal T cell disorder. J Am Acad Dermatol 27:333–336CrossRefPubMedGoogle Scholar
  34. 34.
    Saeki Y, Ohshima S, Kurimoto I, Miura H, Suemura M (2000) Maintaining remission of lupus erythematosus profundus (LEP) with cyclosporin A. Lupus 9:390CrossRefPubMedGoogle Scholar
  35. 35.
    Sanchez NP, Peters MS, Winkelmann RK (1981) The histopathology of lupus erythematosus panniculitis. J Am Acad Dermatol 5:673–680CrossRefPubMedGoogle Scholar
  36. 36.
    Lonceint J, Sassolas B, Lefur JM, Guillet G, Leroy JP (2001) Panniculitis and macrophage activation syndrome in a child with lupus erythematosus. Ann Dermatol Venereol 128:1339–1342 in FrenchPubMedGoogle Scholar
  37. 37.
    D'Cruz D (2001) Antimalarial therapy: a panacea for mild lupus? Lupus 10:148CrossRefPubMedGoogle Scholar
  38. 38.
    Petri M (1996) Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. Lupus 5(Suppl 1):S16–S22CrossRefPubMedGoogle Scholar
  39. 39.
    Khamashta MA, Wallace DJ (eds) (1996) Antimalarials in rheumatology. Lupus 5(Suppl 1):S1–S73.Google Scholar
  40. 40.
    Easterbrook M (1990) Is corneal deposition of antimalarial any indication of retinal toxicity? Can J Ophthalmol 25:249–251PubMedGoogle Scholar
  41. 41.
    Mavrikakis M, Papazoglou S, Sifkakis PP, Vaiopoulos G, Rougas K (1996) Retinal toxicity in long term hydroxychloroquine treatment. Ann Rheum Dis 55:187–189CrossRefPubMedGoogle Scholar
  42. 42.
    Bienfang D, Coblyn JS, Liang MH, Corzillius M (2000) Hydroxychloroquine retinopathy despite regular ophthalmologic evaluation: a consecutive series. J Rheumatol 27:2703–2706PubMedGoogle Scholar
  43. 43.
    Yamada Y, Dekio S, Jidoi J, Ozasa S (1989) Lupus erythematosus profundus: report of a case treated with dapsone. J Dermatol 16:379–382PubMedGoogle Scholar
  44. 44.
    Adu D, Cross J, Jayne DR (2001) Treatment of systemic lupus erythematosus with mycophenolate mofetil. Lupus 10:203–208CrossRefPubMedGoogle Scholar
  45. 45.
    Gaubitz M, Schorat A, Schotte H, Kern P, Domschke W (1999) Mycophenolate mofetil for the treatment of systemic lupus erythematosus: an open pilot trial. Lupus 8:731–736CrossRefPubMedGoogle Scholar
  46. 46.
    Schanz S, Ulmer A, Rassner G, Fierlbeck G (2002) Successful treatment of subacute cutaneous lupus erythematosus with mycophenolate mofetil. Br J Dermatol 147:174–178CrossRefPubMedGoogle Scholar
  47. 47.
    Goyal S, Nousari HC (2001) Treatment of resistant discoid lupus erythematosus of the palms and soles with mycophenolate mofetil. J Am Acad Dermatol 45:142–144CrossRefPubMedGoogle Scholar
  48. 48.
    Boehm I, Bieber T (2001) Chilblain lupus erythematosus Hutchinson: successful treatment with mycophenolate mofetil. Arch Dermatol 137:235–236PubMedGoogle Scholar
  49. 49.
    Knezevic-Maramica I, Kruskall MS (2003) Intravenous immune globulins: an update for clinicians. Transfusion 43:1460–1480CrossRefPubMedGoogle Scholar
  50. 50.
    Kazatchkine MD, Morell A (eds) (1996) Intravenous immunoglobulin research and therapy. Parthenon, New YorkGoogle Scholar
  51. 51.
    Imbach P, Barandun S, d’Apuzzo V et al (1981) High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1:1228–1231CrossRefPubMedGoogle Scholar
  52. 52.
    Shoenfeld Y, Krause I (1996) Immunosuppression and immunomodulation of experimental models of systemic lupus erythematosus and antiphospholipid syndrome. Transplant Proc 28:3096–3098PubMedGoogle Scholar
  53. 53.
    Darabi K, Abdel-Wahab O, Dzik WH (2006) Current usage of intravenous immune globulin and the rationale behind it: the Massachusetts General Hospital data and a review of the literature. Transfusion 46:741CrossRefPubMedGoogle Scholar
  54. 54.
    Onouchi Z, Yanagisawa M, Hirayama T et al (1995) Optimal dosage and differences in therapeutic efficacy of IVIg in Kawasaki disease. Acta Paediatr Jpn 37:40–46PubMedGoogle Scholar
  55. 55.
    Samuelsson A, Towers TL, Ravetch JV (2001) Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291:484CrossRefPubMedGoogle Scholar
  56. 56.
    Fehr J, Hoffman V, Kappeler U (1982) Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin. N Engl J Med 306:1254PubMedGoogle Scholar
  57. 57.
    Tsubakio T, Kurata Y, Katagiri S et al (1983) Alteration of T cell subsets and immunoglobulin synthesis in vitro during high dose gamma globulin therapy in patients with idiopathic thrombocytopenic purpura. Clin Exp Immunol 53:697PubMedGoogle Scholar
  58. 58.
    Dietrich G, Kaveri SV, Kazatchkine MD (1992) Modulation of autoimmunity by intravenous immune globulin through interaction with the function of the immune/idiotypic network. Clin Immunol Immunopathol 62:S73CrossRefPubMedGoogle Scholar
  59. 59.
    Kaveri SV, Dietrich G, Hurez V, Kazatchkine MD (1991) Intravenous immunoglobulins (IVIG) in the treatment of autoimmune diseases. Clin Exp Immunol 86:192PubMedCrossRefGoogle Scholar
  60. 60.
    Jayne DR, Davies MJ, Fox CJ et al (1991) Treatment of systemic vasculitis with pooled intravenous immunoglobulin. Lancet 337:1137CrossRefPubMedGoogle Scholar
  61. 61.
    Palla R, Cirami C, Panichi V et al (1991) Intravenous immunoglobulin therapy of membranous nephropathy: Efficacy and safety. Clin Nephrol 35:98PubMedGoogle Scholar
  62. 62.
    Ashkenazi S, Cleary TG, Lopez E, Pickering LK (1988) Anticytotoxin neutralizing antibodies in immune globulin preparations: potential use in hemolytic–uremic syndrome. J Pediatr 113:1008CrossRefPubMedGoogle Scholar
  63. 63.
    Bleeker WK, Teeling JL, Hack CE (2001) Accelerated autoantibody clearance by intravenous immunoglobulin therapy: studies in experimental models to determine the magnitude and time course of the effect. Blood 98:3136CrossRefPubMedGoogle Scholar
  64. 64.
    Basta M, Van Goor F, Luccioli S et al (2003) F(ab)(2)-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins. Nat Med 9:431CrossRefPubMedGoogle Scholar
  65. 65.
    Sherer Y, Levy Y, Langevitz P, Rauova L, Fabrizzi F, Shoenfeld Y (2001) Adverse effects of intravenous immunoglobulin therapy in 56 patients with autoimmune diseases. Pharmacolgy 62:133–137Google Scholar
  66. 66.
    Rauova L, Lukac J, Levy Y, Rovensky J, Shoenfeld Y (2001) High-dose intravenous immunoglobulins for lupus nephritis—a salvage immunomodulation. Lupus 10:209–213CrossRefPubMedGoogle Scholar
  67. 67.
    Orbach H, Tishler M, Shoenfeld Y (2004) Intravenous immunoglobulin and the kidney—a two-edged sword. Semin Arthritis Rheum 34:593–601CrossRefPubMedGoogle Scholar
  68. 68.
    Pasatiempo AMG, Kroser JA, Rudnick M, Hoffmnann BI (1994) Acute renal failure after intravenous immunoglobulin therapy. J Rheumatol 21:347–349PubMedGoogle Scholar
  69. 69.
    Jordan SC (1989) Intravenous y-globulin therapy in systemic lupus erythematosus and immune complex disease. Ctin Immunol Immunopathol 53:164–169CrossRefGoogle Scholar
  70. 70.
    Hashkes PJ, Lovell DJ (1996) Vasculitis in systemic lupus erythematosus following intravenous immunoglobulin therapy. Clin Exp Rheumatol 14:673–675PubMedGoogle Scholar
  71. 71.
    Reinhart WH, Berchtold PE (1992) Effect of high-dose intravenous immunoglobulin therapy on blood rheology. Lancet 339:662–644CrossRefPubMedGoogle Scholar
  72. 72.
    Dalakas MC (1994) High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology 44:223–226PubMedGoogle Scholar
  73. 73.
    Nishikawa M, Ichiyama T, Hasegawa M, Kawasaki K, Matsubara T, Furukawa S (2003) Safety from thromboembolism using intravenous immunoglobulin therapy in Kawasaki disease: study of whole-blood viscosity. Pediatr Int 45:156–158CrossRefPubMedGoogle Scholar
  74. 74.
    Woodruff RK, Grigg AP, Firkin FC, Smith IL (1986) Fatal thrombotic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulin in elderly patients. Lancet 2:217–218CrossRefPubMedGoogle Scholar
  75. 75.
    Voltz R, Rosen FV, Yousry T, Beck J, Hohlfeld R (1996) Reversible encephalopathy with cerebral vasospasm in a Guillain–Barre syndrome patient treated with intravenous immunoglobulin. Neurology 46:250–251PubMedGoogle Scholar
  76. 76.
    Sztajzel R, Le Floch-Rohr J, Eggimann P (1999) High-dose intravenous immunoglobulin treatment and cerebral vasospasm: a possible mechanism of ischemic encephalopathy? Eur Neurol 41:153–158CrossRefPubMedGoogle Scholar
  77. 77.
    Katz U, Shoenfeld Y (2005) Review: intravenous immunoglobulin therapy and thromboembolic complications. Lupus 14:802CrossRefPubMedGoogle Scholar
  78. 78.
    Go RS, Call TG (2000) Deep venous thrombosis of the arm after intravenous immunoglobulin infusion: case report and literature review of intravenous immunoglobulin-related thrombotic complications. Mayo Clin Proc 75:83–85CrossRefPubMedGoogle Scholar
  79. 79.
    Turner B, Wills AJ (2000) Cerebral infarction complicating intravenous immunoglobulin therapy in a patient with Miller Fisher syndrome. J Neurol Neurosurg Psychiatry 68:790–791CrossRefPubMedGoogle Scholar
  80. 80.
    Shoenfeld Y, Krause I (2004) IVIG for autoimmune, fibrosis, and malignant conditions: our experience with 200 patients. J Clin Immunol 24:107–114CrossRefPubMedGoogle Scholar
  81. 81.
    Sherer Y, Wu R, Krause I, Peter JB, Shoenfeld Y (2001) Antiphospholipid antibody levels in intravenous immunoglobulin (IVIg) preparations. Lupus 10:568. doi: 10.1191/096120301701549705 CrossRefPubMedGoogle Scholar
  82. 82.
    Krause I, Blank M, Shoenfeld Y (1998) Anti-DNA and antiphospholipid antibodies in IVIg preparations: in vivo study in naive mice. J Clin Immunol 18:52–60CrossRefPubMedGoogle Scholar

Copyright information

© Humana Press Inc. 2009

Authors and Affiliations

  • João Espírito Santo
    • 1
    Email author
  • M. F. Gomes
    • 1
  • M. J. Gomes
    • 1
  • L. Peixoto
    • 1
  • S. C. Pereira
    • 1
  • A. Acabado
    • 1
  • J. Freitas
    • 2
  • G. Vinhas de Sousa
    • 1
  1. 1.Departement of Medicine 1Hospital Santa MariaLisbonPortugal
  2. 2.Departement of DermatologyHospital Santa MariaLisbonPortugal

Personalised recommendations